Tenax Therapeutics, Inc. (TENX) - NASDAQ
  • Thu, May 19, 6:28 AM
    • Tenax Therapeutics (TENX) Q1 results: Revenues: $0; R&D Expense: $3.9M (+143.8%); SG&A: $1.8M (+12.5%); Operating Loss: ($5.7M) (-78.1%); Net Loss: ($5.4M) (-86.2%); Loss Per Share: ($0.19) (-90.0%); Quick Assets: $15.8M (-21.8%); CF Ops: ($3.3M) (-32.0%).
    • Financial Guidance: The Company continues to expect that its cash balance, including the fair value of its marketable securities, will be sufficient for it to accomplish its corporate goals through 2017, including the full readout of its ongoing Phase 3 LEVO-CTS trial and a potential New Drug Application for levosimendan in the LCOS indication.
    | Thu, May 19, 6:28 AM
  • Thu, May 19, 1:48 AM
    • Tenax Therapeutics (NASDAQ:TENX): Q1 EPS of -$0.19 misses by $0.05.
    • Cash and cash equivalents of $3.3M.
    • Press Release
    | Thu, May 19, 1:48 AM
  • Wed, Mar. 16, 8:19 AM
    | Wed, Mar. 16, 8:19 AM
  • Dec. 15, 2015, 7:25 AM
    • Tenax Therapeutics (TENX +1%) FQ2 results: Revenues: $0; R&D Expense: $2.5M (-3.8%); SG&A: $1.2M (-25.0%); Operating Loss: ($3.7M) (+9.8%); Net Loss: ($3.5M) (+14.6%); Loss Per Share: ($0.13) (+7.1%); Quick Assets: $21.7M (+26.9%).
    • No guidance given.
    | Dec. 15, 2015, 7:25 AM
  • Dec. 15, 2015, 3:56 AM
    • Tenax Therapeutics (NASDAQ:TENX): FQ2 EPS of -$0.13 beats by $0.01.
    • 10Q
    | Dec. 15, 2015, 3:56 AM
  • Sep. 14, 2015, 6:16 AM
    • Tenax Therapeutics (TENX -0.8%) FQ1 results: Revenues: $0; R&D Expense: $1.7M (+70.0%); SG&A: $1.37M (-5.5%); Operating Loss: ($3.1M) (-29.2%); Net Loss: ($3M) (-36.4%); Loss Per Share: ($0.11) (-37.5%); Quick Assets: $21.3M (+24.6%).
    • No guidance given.
    | Sep. 14, 2015, 6:16 AM
  • Sep. 14, 2015, 6:04 AM
    • Tenax Therapeutics (NASDAQ:TENX): FQ1 EPS of -$0.11 beats by $0.03.
    | Sep. 14, 2015, 6:04 AM
  • Jul. 16, 2015, 6:22 AM
    • Tenax Therapeutics (TENX -1.3%) FY15 results: Revenues: $0; R&D Expense: $6.7M (+123.3%); SG&A: $7.2M (-47.8%); Operating Loss: ($14.8M) (+10.8%); Net Loss: ($14.1M) (+44.3%); Loss Per Share: ($0.50) (+81.5%); Quick Assets: $17.1M (-70.7%).
    • No guidance given.
    | Jul. 16, 2015, 6:22 AM
  • Jul. 16, 2015, 6:05 AM
    • Tenax Therapeutics (NASDAQ:TENX): FY15 EPS of -$0.50
    | Jul. 16, 2015, 6:05 AM
  • Mar. 18, 2015, 6:28 AM
    • Tenax Therapeutics (TENX) FQ3 results: Revenues: $0; R&D Expense: $1.2M (+71.4%); SG&A: $1.9M (+5.6%); Operating Loss: ($3.1M) (-29.2%); Net Loss: ($2.9M) (+14.7%); Loss Per Share: ($0.10) (+77.3%); Quick Assets: $17.1M (-70.7%).
    • No guidance given.
    | Mar. 18, 2015, 6:28 AM
  • Mar. 18, 2015, 6:04 AM
    • Tenax Therapeutics (NASDAQ:TENX): FQ3 EPS of -$0.10 beats by $0.06.
    | Mar. 18, 2015, 6:04 AM
  • Dec. 17, 2014, 6:26 AM
    • Tenax Therapeutics (TENX -1.6%) FQ2 results: Revenues: $0; R&D Expense: $2.6M (+271.4%); G&A: $1.6M (+14.3%); Net Loss: ($4.1M) (-17.1%); Loss Per Share: ($0.14) (+88.8%); Quick Assets: $22.6M (-61.2%).
    • No guidance given.
    | Dec. 17, 2014, 6:26 AM
  • Dec. 17, 2014, 6:03 AM
    • Tenax Therapeutics (NASDAQ:TENX): FQ2 EPS of -$0.14 beats by $0.04.
    | Dec. 17, 2014, 6:03 AM
  • Dec. 10, 2014, 4:53 PM
    • Tenax Therapeutics (NASDAQ:TENX) will report fiscal Q2 results on December 17 before the open. The conference call will begin at 8:30 am ET.
    • Consensus view is a loss of ($0.18) per share.
    | Dec. 10, 2014, 4:53 PM
  • Sep. 24, 2014, 8:37 AM
    • Tenax Therapeutics (NASDAQ:TENX) fiscal Q1 results: Revenues: $0; Operating Expenses: $2.4M (+37.7%); Net Loss: ($2.2M) (+50.0%); Loss Per Share: ($0.08) (+97.6%); Quick Assets: $56.4M (-3.2%).
    • Financial guidance: cash and marketable securities will be sufficient to fund operations through fiscal year 2017.
    | Sep. 24, 2014, 8:37 AM
  • Sep. 24, 2014, 8:06 AM
    • Tenax Therapeutics (NASDAQ:TENX): FQ1 EPS of -$0.08.
    • Cash and cash equivalents $21.96M.
    | Sep. 24, 2014, 8:06 AM
Company Description
Tenax Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market. Its business objective is to discover, develop, and commercialize novel therapeutic products for disease indications that represent... More
Sector: Healthcare
Industry: Biotechnology
Country: United States